Dosing Protocol Key Efficacy Data The STEP clinical trial program demonstrated the following GLP-1 weight loss outcomes with semaglutide 2.4 mg: STEP 1 (adults without diabetes): Mean weight loss of 14.9% at 68 weeks versus 2.4% with placebo (Wilding et al., NEJM , 2021) STEP 2 (adults with type 2 diabetes): Mean weight loss of 9.6% at 68 weeks (Davies et al., Lancet , 2021) STEP 3 (with intensive behavioral therapy): Mean weight loss of 16.0% at 68 weeks (Wadden et al., JAMA , 2021) STEP 5 (long-term 2-year data): Mean weight loss of 15.2% maintained at 104 weeks (Garvey et al., Nature Medicine , 2022) SELECT (cardiovascular outcomes): 20% reduction in MACE in patients with obesity and established CVD without diabetes (Lincoff et al., NEJM , 2023) Clinical Pearls for Semaglutide Prescribing If a patient cannot tolerate the next dose escalation, hold at the current dose for an additional four weeks before reattempting
Plastic Vials: Polypropylene vials are chemically resistant but translucent
B12 Injections: A Personalized Approach to Vitality at Aspire Med Spa and Beauty Bar At Aspire Med Spas, our devotion to customized care is the foundation of our Vitamin B12 injection services
Brenner, S
Growth hormone peptides work similarly to your natural hormones, stimulating the release of growth hormones from the hypothalamus and pituitary gland 3
~ AlphaMD Testosterone Replacement Therapy (TRT) has become a trusted treatment for individuals experiencing symptoms of low testosteronesuch as fatigue, low libido, mood swings, and loss of muscle mass
